ERBB2 and breast cancer: Organoids have advantages in the study of intercellular interaction and immune microenvironment for it can stably carry the EB virus for a long time and mimic intercellular communication involving in exosomes.286 The test results of the breast cancer organoids for the HER-2 targeted drug gefitinib were consistent with the patients’ conditions, indicating that the organ model had similar properties to cancer in vivo.287